Monotherapy after initial diagnosis helps patient compliance

Baltimore-Patients who received latanoprost (Xalatan, Pharmacia Corp., Peapack, NJ) to treat glaucoma were more likely to adhere to their regimens and less likely to discontinue their medications compared with patients who are prescribed beta-blockers, carbonic anhydrase inhibitors, or brimonidine, according to Gail Schwartz, MD, and her colleagues.